Molecular Hydrogen as a Medical Gas for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Possible Efficacy Based on a Literature Review. — CFSMEATLAS
Molecular Hydrogen as a Medical Gas for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Possible Efficacy Based on a Literature Review.
Hirano, Shin-Ichi, Ichikawa, Yusuke, Sato, Bunpei et al. · Frontiers in neurology · 2022 · DOI
Quick Summary
This review examines whether molecular hydrogen (H₂) gas might help treat ME/CFS by fixing problems in the energy-producing parts of cells. The researchers looked at existing studies showing that H₂ can reduce harmful molecules called free radicals and improve fatigue in animals and healthy people. While the idea is promising, the authors emphasize that more human studies are needed before H₂ can be recommended as a treatment.
Why It Matters
This work is important because it identifies a potential mechanism-based therapeutic target for ME/CFS rooted in cellular energy dysfunction—a central feature of the disease. Rather than focusing only on symptom management, this approach suggests a possible path toward treating an underlying biological cause, which could transform how ME/CFS is managed.
Observed Findings
Animal experiments and clinical trials reported H₂ exerted ameliorative effects on acute and chronic fatigue
Molecular hydrogen scavenges hydroxyl radicals, the most potent reactive oxygen species
H₂ ameliorates mitochondrial dysfunction in model systems
Mitochondrial dysfunction plays a major role in abnormal energy metabolism in ME/CFS
Existing ME/CFS treatments have not achieved satisfactory outcomes
Inferred Conclusions
Attenuation of mitochondrial dysfunction by H₂ may be involved in ameliorating fatigue symptoms
H₂ gas may represent an effective medical gas for ME/CFS treatment
Mechanism-based approaches targeting mitochondrial oxidative stress warrant further investigation
Development of curative rather than symptomatic treatments is needed for ME/CFS
Remaining Questions
What is the optimal dose, delivery method, and duration of H₂ treatment in ME/CFS patients?
Does H₂ actually improve mitochondrial function and reduce symptoms in well-designed clinical trials with ME/CFS participants?
What This Study Does Not Prove
This literature review does not provide clinical evidence that H₂ actually works in ME/CFS patients; it is based on extrapolation from animal studies and fatigue research in healthy populations. It does not establish that mitochondrial oxidative stress is the primary driver of ME/CFS symptoms in all patients, nor does it prove that H₂ administration is safe or practical for long-term use in humans with this condition.